Univest
Univest
  • Markets

3 Transmission Towers Maker, Pharmaceuticals Company and Auto Instruments Maker Stocks With a Strong Future Roadmap: Transrail Lighting, Granules India and Pricol

  • November 16, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
3 Transmission Towers Maker, Pharmaceuticals Company and Auto Instruments Maker Stocks With a Strong Future Roadmap: Transrail Lighting, Granules India and Pricol

Transrail Lighting, Granules India and Pricol: ROE of 11.7% to 20.0% and FY22 to FY26 revenue CAGR of 9.2% to 30.9%. Prices as of 13 Nov 2026.

Quick Answer

The three power tower, pharma and auto cluster stocks to watch are Transrail Lighting, Granules India and Pricol. Their return on equity ranges from 11.7% to 20.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 30.9%. Pricol has the highest return on equity at 20.0%, while Transrail Lighting has the fastest revenue growth at 30.9% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.

Power tower, pharma and auto cluster stocks bring together companies with a visible plan for the years ahead. Transrail Lighting, Granules India and Pricol cover a transmission towers maker, a pharmaceuticals company and an auto instruments maker.

This list covers three power tower, pharma and auto cluster stocks with complete current figures: Transrail Lighting, Granules India and Pricol. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Power Tower, Pharma and Auto Cluster Stocks?
  • Power Tower, Pharma and Auto Cluster Stocks at a Glance
  • Why Do Power Tower, Pharma and Auto Cluster Stocks Have a Strong Roadmap in India?
  • Why Transrail Lighting Features Among These Power Tower, Pharma and Auto Cluster Stocks
  • Why Granules India Features Among These Power Tower, Pharma and Auto Cluster Stocks
  • Why Pricol Features Among These Power Tower, Pharma and Auto Cluster Stocks
  • Transrail Lighting vs Granules India vs Pricol on Key Financials
  • Key Risks to Check Before Investing in Power Tower, Pharma and Auto Cluster Stocks
  • Final Thoughts on Power Tower, Pharma and Auto Cluster Stocks
    • What are power tower, pharma and auto cluster stocks?
    • Which power tower, pharma and auto cluster stocks are covered in this list?
    • Why do power tower, pharma and auto cluster stocks have a strong future roadmap in India?
    • How has Transrail Lighting performed financially?
    • How has Granules India performed financially?
    • How has Pricol performed financially?
    • What risks should investors check before buying power tower, pharma and auto cluster stocks?
    • Is this list of power tower, pharma and auto cluster stocks investment advice?

What Are Power Tower, Pharma and Auto Cluster Stocks?

Power tower, pharma and auto cluster stocks are listed companies that build transmission towers and lighting poles for power projects, make tablets and ingredients for global drug makers, and make instrument clusters, pumps and sensors for vehicles. Their earnings depend on power line orders, medicine demand and vehicle output.

Power Tower, Pharma and Auto Cluster Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Transrail Lighting 449.55 5,796 14.3 22.1 17.7 0.30
Granules India 813.2 22,002 33.2 36.0 11.7 0.30
Pricol 747.85 8,072 30.1 36.9 20.0 0.30

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing power tower, pharma and auto cluster stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in power tower, pharma and auto cluster stocks can use the coming numbers to test whether growth is holding.

Why Do Power Tower, Pharma and Auto Cluster Stocks Have a Strong Roadmap in India?

Power tower, pharma and auto cluster stocks have a strong roadmap in India because heavy spending on power lines, steady demand for quality medicines and rising vehicle technology content keep widening the market for these companies.

  • Transmission towers. The grid needs more power lines.
  • Pharmaceuticals. Patients need quality medicines.
  • Auto instruments. Vehicles carry more digital displays.

Why Transrail Lighting Features Among These Power Tower, Pharma and Auto Cluster Stocks

Among the power tower, pharma and auto cluster stocks on this list, Transrail Lighting is a Vadodara-based engineering, procurement and construction company that builds power transmission and distribution lines and makes transmission towers, poles and conductors.

The company has a return on equity of 17.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 5,796 crore. The stock trades at a P/E of 14.3, below the industry P/E of 22.1.

Revenue rose from Rs 2,357 crore in FY22 to Rs 6,929 crore in FY26, a compound annual growth rate of 30.9%. Net profit grew from Rs 65.2 crore in FY22 to Rs 404 crore in FY26, which works out to a compound annual growth rate of 57.7%. In the June 2026 quarter, revenue grew 4.9% year on year to Rs 1,753 crore, while net profit rose 1.9% to Rs 108 crore.

Roadmap: The company is growing through new transmission projects in India and overseas and through its own manufacturing of towers and related products. Government spending on grid expansion supports a healthy flow of tenders.

What to watch: Track order book additions, project execution and overseas contracts.

Why Granules India Features Among These Power Tower, Pharma and Auto Cluster Stocks

Among the line structure, tablet and instrument panel shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Why Pricol Features Among These Power Tower, Pharma and Auto Cluster Stocks

Among the three companies on this list, Pricol, based in Coimbatore, makes instrument clusters, driver information systems, sensors and pumps for two-wheelers, commercial vehicles and off-highway vehicles.

In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%.

Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9.

Roadmap: Digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.

What to watch: Track the shift to digital clusters and the progress of new product ramp-ups.

Transrail Lighting vs Granules India vs Pricol on Key Financials

The table below sets the three power tower, pharma and auto cluster stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Transrail Lighting 2,357 6,929 30.9% 404 5.8%
Granules India 3,783 5,386 9.2% 595 11.0%
Pricol 1,554 4,052 27.1% 251 6.2%

Pricol posts the highest return on equity in this group at 20.0%. Transrail Lighting combines the largest FY26 revenue at Rs 6,929 crore with the fastest revenue growth, a 30.9% compound annual rate. A useful habit with power tower, pharma and auto cluster stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Transrail Lighting 1,671 1,753 4.9%
Granules India 1,226 1,479 20.6%
Pricol 898 1,108 23.4%

Key Risks to Check Before Investing in Power Tower, Pharma and Auto Cluster Stocks

Every theme carries risks that deserve a check before any decision. For these power tower, pharma and auto cluster stocks, the main points are: Long-term line structure, tablet and instrument panel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Order timing. Project awards can shift between periods.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Production cycles. Vehicle output can vary with demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter power tower, pharma and auto cluster stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Power Tower, Pharma and Auto Cluster Stocks

Power tower, pharma and auto cluster stocks suit investors who prefer to study business strength before price moves. Transrail Lighting, Granules India and Pricol each have a clear plan to grow. Based on the 13 November 2026 close, Transrail Lighting trades at Rs 449.55, Granules India at Rs 813.2 and Pricol at Rs 747.85. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these power tower, pharma and auto cluster stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track power tower, pharma and auto cluster stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are power tower, pharma and auto cluster stocks?

Ans. Power tower, pharma and auto cluster stocks are listed companies that build transmission towers and lighting poles for power projects, make tablets and ingredients for global drug makers, and make instrument clusters, pumps and sensors for vehicles. Their earnings depend on power line orders, medicine demand and vehicle output. This list looks at three of them, Transrail Lighting, Granules India and Pricol, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.

Which power tower, pharma and auto cluster stocks are covered in this list?

Ans. This list covers Transrail Lighting, Granules India and Pricol. Based on the 13 November 2026 close, Transrail Lighting traded at Rs 449.55, Granules India at Rs 813.2 and Pricol at Rs 747.85. Their return on equity ranges from 11.7% to 20.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 30.9%.

Why do power tower, pharma and auto cluster stocks have a strong future roadmap in India?

Ans. Power tower, pharma and auto cluster stocks have a strong roadmap in India because heavy spending on power lines, steady demand for quality medicines and rising vehicle technology content keep widening the market for these companies. The main drivers are as follows. Transmission towers. The grid needs more power lines. Pharmaceuticals. Patients need quality medicines. Auto instruments. Vehicles carry more digital displays. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Transrail Lighting performed financially?

Ans. Revenue rose from Rs 2,357 crore in FY22 to Rs 6,929 crore in FY26, a compound annual growth rate of 30.9%. Net profit grew from Rs 65.2 crore in FY22 to Rs 404 crore in FY26, which works out to a compound annual growth rate of 57.7%. In the June 2026 quarter, revenue grew 4.9% year on year to Rs 1,753 crore, while net profit rose 1.9% to Rs 108 crore. The company has a return on equity of 17.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 5,796 crore. The stock trades at a P/E of 14.3, below the industry P/E of 22.1. Looking ahead, the company is growing through new transmission projects in India and overseas and through its own manufacturing of towers and related products. Government spending on grid expansion supports a healthy flow of tenders.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

How has Pricol performed financially?

Ans. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9. Looking ahead, digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.

What risks should investors check before buying power tower, pharma and auto cluster stocks?

Ans. Investors should check a few risks before buying power tower, pharma and auto cluster stocks. Order timing. Project awards can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of power tower, pharma and auto cluster stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks formulations and vehicle display stocks Granules India line structure pharma and auto cluster stocks power tower Pricol tablet and instrument panel shares transmission works Transrail Lighting
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply